Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Asset Utilization Ratio data on record, last reported at 0.14 in Q4 2025.

  • For Q4 2025, Asset Utilization Ratio rose 58.99% year-over-year to 0.14; the TTM value through Dec 2025 reached 0.14, up 58.99%, while the annual FY2025 figure was 0.13, 45.39% up from the prior year.
  • Asset Utilization Ratio reached 0.14 in Q4 2025 per LCTX's latest filing, up from 0.12 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.14 in Q4 2025 and bottomed at 0.01 in Q2 2021.
  • Average Asset Utilization Ratio over 5 years is 0.08, with a median of 0.09 recorded in 2024.
  • Peak YoY movement for Asset Utilization Ratio: crashed 43.11% in 2021, then skyrocketed 543.84% in 2022.
  • A 5-year view of Asset Utilization Ratio shows it stood at 0.03 in 2021, then surged by 334.99% to 0.12 in 2022, then decreased by 25.53% to 0.09 in 2023, then grew by 5.36% to 0.09 in 2024, then surged by 58.99% to 0.14 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Utilization Ratio were 0.14 in Q4 2025, 0.12 in Q3 2025, and 0.11 in Q2 2025.